The Edit Health Review: It Tells You Which Pharmacy, Then Sells You Sleep

The thing almost nobody does

Start with what The Edit gets right, because it is unusual enough to be the reason this review exists.

Open its help centre and ask where the medication comes from. The answer is one sentence with a proper noun in it: "Every prescription is filled by The Pharmacy Hub, a licensed U.S. pharmacy, and shipped directly to your door."

That is a fact you can act on. The Pharmacy Hub is a compounding and fulfilment pharmacy in Miami, Florida, carrying NPI 1316684616. A patient holding a vial can look it up. Across the telehealth peptide market, the normal answer to the same question is "a state-licensed pharmacy in our network" — a category, not a name — and a customer who wants to know who made the thing they are injecting has no route at all.

The Edit names the other half of the chain too. Clinical care comes from "licensed medical providers (physicians, nurse practitioners, and physician assistants) at our affiliated medical practice, Arora Health & Aesthetics, LLC, who hold sole authority over all medical decisions and prescribing." The Edit Health LLC describes itself as the management services organisation and says outright that it "does not practice medicine and is not a pharmacy." That is the actual legal structure of nearly every company in this category, and it is written down here rather than blurred.

One caveat, reported because it is real. The shipping policy — the governing document, not the marketing page — describes fulfilment by "one of our partner pharmacies (collectively, the 'The Edit Health Pharmacy Network'), which may include The Pharmacy Hub as the dispensing pharmacy." "Every prescription is filled by X" and "a network which may include X" are different promises. Both are published today.

Sermorelin, and a sentence with no hedge in it

Here is the load-bearing claim on the sermorelin page, verbatim: "Sermorelin signals your body to release its own growth hormone, the way it did when you were younger. That signal fades with age. Restoring it supports deeper sleep, faster recovery, and lean muscle."

The first clause is true. Sermorelin is the 1-29 fragment of growth-hormone-releasing hormone, and it does prompt the pituitary to release GH. That is why it existed — largely as a diagnostic agent.

Everything after "Restoring it" is where the sentence outruns the evidence. As of August 2026, a PubMed search for sermorelin filtered to the randomised-controlled-trial publication type returns 19 records. The newest was published in 2005. ⁵ They are studies of GH response to a challenge, of growth in children with GH deficiency, of dose-response to a bolus. Not one measures sleep quality, recovery, or lean body mass in healthy adults.

Search from the other direction and the answer is the same. A PubMed search for sermorelin in title or abstract combined with sleep returns exactly one record, and it is a 2026 review article, not a trial. On ClinicalTrials.gov, 27 studies list sermorelin as an intervention; the two that come closest to this marketed use are both phase 2 and both terminated, at 13 and 5 participants.

Worth noticing how the sentence is built. Competitors selling the same molecule write "may help support." The Edit writes "Restoring it supports." The hedge is gone, and the evidence behind the unhedged version is the same evidence — which is to say, none for these three outcomes.

If you want the whole picture on growth-hormone-axis peptides rather than one company's product page, that is a compound question, and the evidence pages are where it belongs.

The copper cream, which has actually been tested

The GHK-Cu page is the most interesting product on the site, because unlike the others it makes a claim somebody has already run a randomised trial on.

The claim: "Applied topically, it supports firmer skin, smoother texture, and overall skin renewal." The benefit tiles are more specific still — "Softened fine lines: texture smooths over weeks of daily use." And, under who it is for, "Post-procedure recovery: supporting your skin after microneedling, laser, or peels."

That last one has a trial. In 2006, patients undergoing CO2 laser skin resurfacing were randomised to a post-treatment regimen with or without GHK-Cu skincare, with blinded evaluators and computer analysis of erythema, and a validated questionnaire before and twelve weeks after. Thirteen patients completed it. The finding, in the authors' own words: "Objective evaluation found no significant improvement in wrinkles or overall skin quality." What did differ was how satisfied patients said they were. ³

So the claim closest to being testable was tested, and the objective endpoints did not move. That is not the same as proof the product does nothing — thirteen patients is a very small trial, and a null result at that size is weak evidence. It is, however, the only randomised evidence there is, and it points the other way from the page.

The registry does not rescue it. As of August 2026, ClinicalTrials.gov lists three studies with GHK-Cu as an intervention. The highest-phase one, NCT07437586, is phase 2, recruiting, sixty participants estimated, and it studies a gel for acute skin wound healing — not a cream for fine lines. ⁴ It has produced no results. A third listing surfaces in a GHK-Cu search only because a hydrafacial device trial includes a GHK-bearing serum in one arm; it is a study of the device, not the peptide.

NAD+ at $249, and the empty search

The most expensive product on the site is the one with the least behind it.

The NAD+ page sells "steadier energy," "sharper focus," "clearer thinking without the caffeine swing," and "healthy aging" — delivered by subcutaneous injection, with a nasal spray listed as coming soon.

As of August 2026, a PubMed search for "nicotinamide adenine dinucleotide" in title or abstract, combined with subcutaneous or injection, filtered to the randomised-controlled-trial publication type, returns zero records. ⁸ Not a small literature with mixed results. Zero.

There is a real and genuinely interesting literature on oral NAD+ precursors. It concerns different molecules taken by a different route, and it does not transfer to an injection any more than the evidence for oral iron transfers to an iron infusion. The glutathione injection sits in the same position: the randomised glutathione-and-skin literature that exists is oral and topical, measuring melanin index in whitening studies ^{6 7}, and none of it studies the injection The Edit sells.

The one paragraph missing from every page

There is a sentence The Edit has already written, correctly, in plain language:

"Compounded medications are not FDA-approved. The FDA does not evaluate compounded products for safety, effectiveness, or quality."

It appears in llms.txt — the file written for AI crawlers.

It does not appear on the tirzepatide page, the semaglutide page, the sermorelin page, the NAD+ page, the glutathione page or the GHK-Cu page. Those pages carry a different line: "This treatment requires licensed provider review and approval," plus "Compounded" as a small label beside the product name. The help centre gets closest, telling readers that compounded semaglutide and tirzepatide are "not affiliated with, endorsed by, or a substitute for" the branded products — true, and not the same statement.

The company knows the sentence. It has typed it. It put it in front of the machines and not in front of the patients, and that is a choice about placement rather than a gap in understanding — which makes it the easiest thing on this entire page for The Edit to fix.

What testing does and does not mean here

The Edit's testing disclosure is one line, in a rotating marquee on the home page: "Dispensed by The Pharmacy Hub, batch-tested for potency and sterility."

Both of the right things are named. Potency tells you the vial is the strength the label says; sterility tells you it is not contaminated. "Batch-tested" implies per-lot rather than periodic sampling, which is the stronger claim.

What is not published: which standard sterility is tested against, what potency tolerance is accepted, whether endotoxin or pH are tested at all, which laboratory does the work, and — the one a customer could actually use — a certificate of analysis for any lot. Sellers who publish a testing programme and sellers who publish a lot report are making different claims, and this is the first kind.